Harel contributed to drug discovery technology developer Eikon Therapeutics' $518m series B round while a host of corporates are set to exit data management software provider Trifacta in a $400m acquisition.

Funding Eikon Therapeutics, a US-based developer of microscopy drug discovery technology, raised approximately $518m yesterday in a series B round featuring insurance firm Harel Insurance. It was joined by T Rowe Price, Canada Pension Plan Investment Board, EcoR1 Capital, UC Investments, Abu Dhabi Investment Authority’s ADIA subsidiary, StepStone Group, Soros Capital, Schroders Capital, General Catalyst,…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.